Supporting data for "Enhancing Neoantigen Cancer Vaccine Efficacy with a Self-assembly Peptide-Adjuvant Conjugates Nanoparticle Platform"

In this study, we used synthetic neoantigen peptides conjugated with Toll-like receptor 7 agonist (TLR7a) adjuvants, resulting in the formation of a self-assembling peptide adjuvant conjugates nanoparticle (SaPAC) therapeutic cancer vaccine. We found that SaPAC platform enhances immunogenicity of neoantigen preloaded by increasing the antigen uptake by dendritic cells (DCs) and further maturating DCs in draining lymph nodes from mice. Our data demonstrated the versatile applicability of the SaPAC platform in carrying various neoantigens against different mouse cancer models including melanoma B16OVA, bladder cancer MB49 and breast cancer 4T1(with anti-PD1) in vivo, resulting in a robust anti-tumor response. These findings provide valuable insights into the development of synthetic peptide-based cancer vaccines and demonstrate the feasibility of the SaPAC platform for the delivery of personalized neoantigen-based cancer immunotherapy.